1. Apoptosis Immunology/Inflammation GPCR/G Protein
  2. Apoptosis COX NO Synthase Interleukin Related Prostaglandin Receptor TNF Receptor
  3. Lornoxicam

Lornoxicam  (Synonyms: 氯诺昔康; Chlortenoxicam; Ro 13-9297)

目录号: HY-B0367 纯度: 99.36%
COA 产品使用指南 技术支持

Lornoxicam (Chlortenoxicam) 是一种具有口服活性的奥昔康类非甾体抗炎药 (NSAID),具有镇痛,抗炎,解热和抗癌活性。Lornoxicam 对 COX-1COX-2 均表现出良好的抑制作用 (COX-1: IC50=0.005 μM; COX-2: IC50=0.008 μM) 并抑制 iNOS 生成 NO (IC50=65 μM) 和促炎细胞因子 IL-6 (IC50=54 μM) 的产生。Lornoxicam 还抑制肿瘤细胞增殖和迁移并诱导肿瘤细胞凋亡 (apoptosis)。Lornoxicam 可用于炎症性疼痛,结直肠癌和乳腺癌的研究。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Lornoxicam Chemical Structure

Lornoxicam Chemical Structure

CAS No. : 70374-39-9

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥275
In-stock
100 mg ¥250
In-stock
200 mg ¥400
In-stock
500 mg ¥800
In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Lornoxicam:

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Lornoxicam (Chlortenoxicam) is an orally active oxycontin nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, antipyretic and anticancer activities. Lornoxicam exhibits good inhibitory effects on both COX-1 and COX-2 (COX-1: IC50=0.005 μM; COX-2:IC50=0.008 μM) and inhibits the production of NO by iNOS (IC50=65 μM) and the proinflammatory cytokine IL-6 (IC50=54 μM). Lornoxicam also inhibits tumor cell proliferation and migration and induces tumor cell apoptosis. Lornoxicam can be used in the study of inflammatory pain, colorectal cancer and breast cancer[1][2][3][4][5][6][7].

IC50 & Target[1]

COX-1

5 nM (IC50, in cells)

COX-2

45 nM (IC50, in cells)

体外研究
(In Vitro)

Lornoxicam (0.03-3 μM; 24 h) 剂量依赖性地抑制 HEL 细胞中 TXB2 的形成,抑制 LPS (HY-D1056) 刺激的 Mono Mac 6 细胞中 PGF1 的形成和 LPS (HY-D1056) 刺激的 RAW 264.7 细胞上清液中 NO 的积累[6]
Lornoxicam (10-300 μM; 10 min) 剂量依赖性地抑制人类单核细胞 THP-1 中 IL-6 的形成 (IC50=54 μM),并在 300 μM 的剂量下弱刺激 TNF-a, IL-1b 和 IL-8 的产生[6]
Lornoxicam (3.1-400 μg/mL; 0-48 h) 浓度依赖性诱导宫颈癌、结直肠癌和乳腺癌细胞系 HeLa、MCF-7 和 HT-29 的活力降低并抑制 HT-29 细胞系增殖[7]
Lornoxicam (400 μg/mL; 24 h) 诱导 HT-29 和 MCF-7 肿瘤细胞凋亡的发生[7]
Lornoxicam (400 μg/mL; 0-72 h) 抑制 HT-29 和 MCF-7 肿瘤细胞的迁移[7]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[7]

Cell Line: HeLa, MCF-7 and HT-29 tumor cell lines
Concentration: 3.1, 6.3, 12.5, 25, 50, 100, 200 and 400 μg/mL
Incubation Time: 24 and 48 h
Result: Induced a statistically significant reduction of the viability of HeLa tumor cells only at concentrations of 200 μg/mL and 400 μg/mL after 24 h and at all tested concentrations after 48 h of exposure.

Cell Proliferation Assay[7]

Cell Line: HT-29 tumor cell lines
Concentration: 3.1, 6.3, 12.5, 25, 50, 100, 200 and 400 μg/mL
Incubation Time: 24 and 48 h
Result: Antiproliferative effects of lornoxicam on HT-29 cells at concentrations of 100, 200, and 400 μg/mL.

Apoptosis Analysis[7]

Cell Line: HT-29 and MCF-7 tumor cell lines
Concentration: 400 μg/mL
Incubation Time: 24 h
Result: Induced morphological characteristics of early and late apoptosis in HT-29 cells.
Led to condensation and margination of chromatin in the nuclei of MCF-7 cells.

Cell Migration Assay [7]

Cell Line: HT-29 and MCF-7 tumor cell lines
Concentration: 400 μg/mL
Incubation Time: 24, 48 and 72 h
Result: The migration percentages of HT-29 tumor cell were 12.34%, 18.28%, and 18.61% at 24, 48 and 72 h.
The migration percentages of MCF-7 tumor cell were 3.85%, 7.77%, and 9.06% at 24, 48 and 72 h.
体内研究
(In Vivo)

Lornoxicam (1.3 mg/kg, i.p.; 单剂量注射) 减少热后爪痛觉过敏模型的大鼠中枢致敏的能力,从而减少痛觉过敏[3]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Rats with thermal hind paw hyperalgesia model induced by tail injection of 10% formaldehyde[3].
Dosage: 1.3 mg/kg
Administration: Intraperitoneal injection (i.p.); Single dose injection 30 minutes before 10% formaldehyde
Result: Produced anti-inflammatory effects, did not alter thermal nociceptive thresholds, and completely blocked hindlimb hyperalgesia.
Clinical Trial
分子量

371.82

Formula

C13H10ClN3O4S2

CAS 号
性状

固体

颜色

Light yellow to yellow

中文名称

氯诺昔康

结构分类
初始来源
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验: 

DMSO 中的溶解度 : 3.8 mg/mL (10.22 mM; 超声加热助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6895 mL 13.4474 mL 26.8947 mL
5 mM 0.5379 mL 2.6895 mL 5.3789 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物溶解方案计算器
请输入动物实验的基本信息:

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

由于实验过程有损耗,建议您多配一只动物的量
计算结果
工作液所需浓度 : mg/mL
纯度 & 产品资料

纯度: 99.36%

参考文献

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.6895 mL 13.4474 mL 26.8947 mL 67.2368 mL
5 mM 0.5379 mL 2.6895 mL 5.3789 mL 13.4474 mL
10 mM 0.2689 mL 1.3447 mL 2.6895 mL 6.7237 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Lornoxicam
目录号:
HY-B0367
需求量: